Jing‐Yun Wen

783 total citations
36 papers, 594 citations indexed

About

Jing‐Yun Wen is a scholar working on Oncology, Epidemiology and Hepatology. According to data from OpenAlex, Jing‐Yun Wen has authored 36 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Epidemiology and 14 papers in Hepatology. Recurrent topics in Jing‐Yun Wen's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Liver Disease Diagnosis and Treatment (10 papers) and Cancer, Lipids, and Metabolism (8 papers). Jing‐Yun Wen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Liver Disease Diagnosis and Treatment (10 papers) and Cancer, Lipids, and Metabolism (8 papers). Jing‐Yun Wen collaborates with scholars based in China, United States and Hong Kong. Jing‐Yun Wen's co-authors include Xiaokun Ma, Zhan‐Hong Chen, Dong‐Hao Wu, Xing Li, Qu Lin, Dan‐Yun Ruan, Min Dong, Xiangyuan Wu, Wei Li and Tiantian Wang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Letters and International Journal of Biological Macromolecules.

In The Last Decade

Jing‐Yun Wen

35 papers receiving 588 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jing‐Yun Wen China 13 255 210 199 175 172 36 594
Yadi Liao China 16 126 0.5× 137 0.7× 185 0.9× 204 1.2× 250 1.5× 21 582
Osamu Okochi Japan 9 183 0.7× 105 0.5× 116 0.6× 125 0.7× 205 1.2× 26 518
Bijun Qiu China 12 185 0.7× 139 0.7× 197 1.0× 98 0.6× 445 2.6× 29 691
Mami Kanamoto Japan 19 273 1.1× 150 0.7× 134 0.7× 241 1.4× 173 1.0× 43 712
Ye Jin Ha South Korea 13 154 0.6× 320 1.5× 89 0.4× 184 1.1× 160 0.9× 27 615
Yih-Jyh Lin Taiwan 14 110 0.4× 122 0.6× 104 0.5× 162 0.9× 149 0.9× 23 501
Dana A. Dominguez United States 12 206 0.8× 103 0.5× 188 0.9× 129 0.7× 223 1.3× 39 685
Zhixiang Jian China 17 335 1.3× 143 0.7× 180 0.9× 195 1.1× 206 1.2× 38 781
Hideki Ueno Japan 14 389 1.5× 132 0.6× 168 0.8× 160 0.9× 192 1.1× 44 706
Oxana V. Makarova‐Rusher United States 10 334 1.3× 232 1.1× 116 0.6× 269 1.5× 133 0.8× 17 707

Countries citing papers authored by Jing‐Yun Wen

Since Specialization
Citations

This map shows the geographic impact of Jing‐Yun Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing‐Yun Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing‐Yun Wen more than expected).

Fields of papers citing papers by Jing‐Yun Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jing‐Yun Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing‐Yun Wen. The network helps show where Jing‐Yun Wen may publish in the future.

Co-authorship network of co-authors of Jing‐Yun Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Jing‐Yun Wen. A scholar is included among the top collaborators of Jing‐Yun Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jing‐Yun Wen. Jing‐Yun Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Shaolin, Li‐ping Gong, Yuhang Pan, et al.. (2024). PPM1G promotes cell proliferation via modulating mutant GOF p53 protein expression in hepatocellular carcinoma. iScience. 27(3). 109116–109116. 1 indexed citations
2.
Wen, Jing‐Yun, Xing Li, Jianning Chen, et al.. (2023). CD45− erythroid progenitor cells promote lymph node metastasis in gastric cancer by inducing a hybrid epithelial/mesenchymal state in lymphatic endothelial cells. Gastric Cancer. 26(6). 918–933. 2 indexed citations
3.
Gong, Li‐ping, Lijie Pan, Zhiying Feng, et al.. (2022). ebv-circRPMS1 promotes the progression of EBV-associated gastric carcinoma via Sam68-dependent activation of METTL3. Cancer Letters. 535. 215646–215646. 28 indexed citations
4.
Gong, Li‐ping, Jing‐Yun Wen, Liping Sun, et al.. (2022). EBV-Induced CXCL8 Upregulation Promotes Vasculogenic Mimicry in Gastric Carcinoma via NF-κB Signaling. Frontiers in Cellular and Infection Microbiology. 12. 780416–780416. 6 indexed citations
5.
Chen, Yongjian, Yunfang Yu, Jing‐Yun Wen, et al.. (2021). Prognostic and immunological role of CD36: A pan-cancer analysis. Journal of Cancer. 12(16). 4762–4773. 32 indexed citations
6.
Gong, Li‐ping, Zhiying Feng, Yuhang Pan, et al.. (2021). Hypoxia-induced ebv-circLMP2A promotes angiogenesis in EBV-associated gastric carcinoma through the KHSRP/VHL/HIF1α/VEGFA pathway. Cancer Letters. 526. 259–272. 42 indexed citations
7.
8.
Li, Wei, Jing‐Yun Wen, Jie Chen, et al.. (2019). Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer. World Journal of Gastroenterology. 25(37). 5590–5603. 29 indexed citations
9.
Cai, Xiurong, Zhan‐Hong Chen, Xiaoping Zhang, et al.. (2018). Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. Journal of Cancer. 9(13). 2380–2388. 12 indexed citations
10.
Chen, Zhan‐Hong, Xing Li, Dong‐Hao Wu, et al.. (2017). Validation and ranking of seven staging systems of hepatocellular carcinoma. Oncology Letters. 14(1). 705–714. 21 indexed citations
11.
Wu, Dong‐Hao, Tiantian Wang, Dan‐Yun Ruan, et al.. (2017). Combination of ULK1 and LC3B improve prognosis assessment of hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 97. 195–202. 32 indexed citations
12.
Li, Xing, Xiang Zhong, Zhan‐Hong Chen, et al.. (2016). Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization. Asian Pacific Journal of Cancer Prevention. 16(18). 8665–8670. 10 indexed citations
13.
14.
Chen, Zhan‐Hong, Xiaokun Ma, Xing Li, et al.. (2015). Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma. Tumor Biology. 37(4). 5265–5273. 5 indexed citations
15.
Li, Xing, Xiang Zhong, Zhan‐Hong Chen, et al.. (2014). Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients. Asian Pacific Journal of Cancer Prevention. 15(22). 9635–9641. 11 indexed citations
16.
Wu, Dong‐Hao, Changchang Jia, Jie Chen, et al.. (2014). Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. Tumor Biology. 35(12). 12225–12233. 77 indexed citations
17.
Wen, Jing‐Yun, Mai Suan Li, Xing Li, et al.. (2014). Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study. Asian Pacific Journal of Cancer Prevention. 15(15). 6275–6281. 8 indexed citations
18.
Ma, Xiaokun, Jing‐Yun Wen, Zhan‐Hong Chen, et al.. (2013). Clinical significance of plasma fibrinogen level in patients with prostate cancer.. Journal of Clinical Oncology. 31(15_suppl). e16077–e16077. 2 indexed citations
19.
Wu, Xiangyuan, Xing Li, Zhan‐Hong Chen, et al.. (2012). An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumor Biology. 34(2). 909–918. 7 indexed citations
20.
Li, Xing, Qu Lin, Min Dong, et al.. (2010). Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leukemia & lymphoma. 51(9). 1678–1685. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yadi Liao Breakdown of academic impact, for papers by Osamu Okochi Breakdown of academic impact, for papers by Bijun Qiu Breakdown of academic impact, for papers by Mami Kanamoto Breakdown of academic impact, for papers by Ye Jin Ha Breakdown of academic impact, for papers by Yih-Jyh Lin Breakdown of academic impact, for papers by Dana A. Dominguez Breakdown of academic impact, for papers by Zhixiang Jian Breakdown of academic impact, for papers by Hideki Ueno Breakdown of academic impact, for papers by Oxana V. Makarova‐Rusher
Rankless by CCL
2026